Akari医疗公共 AKTX 深 沪
已收盘 12-19 16:00:00 美东时间
0.2602
+0.015
+6.20%
华盛通- 最 高0.5999
- 今 开0.2411
- 成交量 177.12万股
- 最 低 0.2178
- 昨 收 0.245
- 总市值 1544.27万
- 52周最高 1.7225
- 市盈率 静 --
- 换手率 2.98%
- 52周最低 0.2178
- 委 比 -66.83%
- 总股本 5934.92万
- 历史最高 250.00
- 量 比 0.47
- 振 幅 155.96%
- 历史最低 0.00
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Akari Therapeutics Appoints Kameel D. Farag As Interim Chief Financial Officer
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the appointment of Kameel D. Farag as its Interim Chief Financial
11-18 21:41
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
Akari Therapeutics received an Indian patent for its immuno-oncology PH1 payload, enhancing its global IP and targeting India's rising cancer rates. PH1 inhibits RNA splicing, killing cancer cells and boosting the immune system, with applications across various cancers. The company aims to expand its ADC technology globally.
06-18 12:50
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics announced positive results from the Phase 1 study of KT-621, an oral STAT6 degrader, showing robust STAT6 degradation, favorable safety profile, and encouraging Th2 biomarker reductions. The drug is expected to advance into Phase 2b trials in AD and asthma in late 2025 and early 2026.
06-02 11:00
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
Akari Therapeutics, a leading oncology biotech company, introduces a video featuring its new Head of Business Development, Mark F. Kubik, highlighting its innovative ADC platform targeting cancer. Its lead candidate, AKTX-101, uses a novel PH1 payload to disrupt RNA splicing, showing significant activity and survival benefits in preclinical studies. The company continues advancing its lead asset and exploring new targets.
05-29 13:15
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Akari Therapeutics CEO Abizer Gaslightwala will present at a virtual biotech investment webinar on May 29 at 2:00 PM ET. Akari is developing next-generation payload ADCs, with lead candidate AKTX-101 targeting Trop2 receptor and utilizing a novel spliceosome inhibitor payload PH1. The company highlights preclinical success of AKTX-101, demonstrating significant activity, prolonged survival, and potential synergy with checkpoint inhibitors.
05-22 13:00
Akari Therapeutics Appoints Samir R. Patel As Interim CEO; Plans For Prioritization Of Peak Bio's ADC Cancer Therapeutic Platform Technology And Akari's PAS-Nomacopan For Geographic Atrophy
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Existing Investors Support the Company with Issuanc...
2024-08-20 04:26
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
11:19 AM EDT, 08/15/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 1.22% to 1,444.66 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and in...
2024-08-15 23:19
